These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 7053265

  • 1. Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma.
    Cancer Treat Rep; 1982 Jan; 66(1):49-55. PubMed ID: 7053265
    [Abstract] [Full Text] [Related]

  • 2. Investigation of the additive potential of teniposide and vincristine in non-Hodgkin's lymphoma. Australian and New Zealand Lymphoma Group.
    Cancer Treat Rep; 1986 Aug; 70(8):985-90. PubMed ID: 2873890
    [Abstract] [Full Text] [Related]

  • 3. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF, Su YS, Liu DG, Jiang WQ, He YJ, Lin TY, Huang HQ, Zhang L, Xia ZJ, Li YH, Zhou ZM, Chen XQ, Xia Y, Zhen ZJ, Guan ZZ.
    Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
    O'Connell MJ, Anderson J, Merrill JM, Bennett JM, Glick JH, Berard CW, Neiman RS, Brodovsky HS.
    Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
    [Abstract] [Full Text] [Related]

  • 6. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D, Graziano F, Mari D, Cetto G, Pasini F, Antonio S, Isidori P, Gasparini S.
    Anticancer Res; 1994 Dec; 14(5B):2221-7. PubMed ID: 7840527
    [Abstract] [Full Text] [Related]

  • 7. Combinations of methotrexate (COP or CHOP) in the treatment of previously untreated and treated lymphomas.
    Gomez GA, Stutzman L, Moayeri H, Shimaoka K, Plager J, Han T, Naeher C, Henderson E.
    Cancer Treat Rep; 1982 Jan; 66(1):43-7. PubMed ID: 6975659
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 Jan; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 10. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.
    Hansen MM, Bloomfield CD, Jørgensen J, Ersbøll J, Pedersen-Bjergaard J, Blom J, Nissen NI.
    Cancer Treat Rep; 1980 Jan; 64(10-11):1135-7. PubMed ID: 7459900
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (VEPA) for non-Hodgkin's lymphoma].
    Saaki A, Yokomatsu Y, Kojima K, Yoshikawa T, Sannomiya Y, Tatsumi J, Hashimoto K, Park K, Kawarabayashi K, Yoshikawa C.
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):65-9. PubMed ID: 3753642
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of a high-dose regimen of cyclophosphamide and prednisolone in advanced non-Hodgkin's lymphoma of favorable histologic type.
    Bell R, Gallagher CJ, Ford J, Malpas JS, Lister TA.
    Cancer Treat Rep; 1982 Feb; 66(2):377-80. PubMed ID: 7055819
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
    Akutsu M, Kano Y, Ogawa M, Miura A, Hirano M, Masaoka T, Tatsumi N.
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
    [Abstract] [Full Text] [Related]

  • 19. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
    Yoshida T, Nakanishi J, Ito K, Kobayashi S, Ohtake S, Nakamura S, Hattori K.
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.